Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CNBX PharmaceuticalsCNBX +33.33% Market Cap is $0.32 Mil as of Aug. 27, 2026. The stock has 3 warning signs investors should review. Among 1,421 Biotechnology companies, CNBX Pharmaceuticals ranks worse than 99.16% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). CNBX Pharmaceuticals's share price for the quarter that ended in May. 2026 was $0.0002. CNBX Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in May. 2026 was 1,475.77 Mil. Therefore, CNBX Pharmaceuticals's market cap for the quarter that ended in May. 2026 was $0.30 Mil.
CNBX Pharmaceuticals's quarterly market cap
declined
from Nov. 2025 ($0.30 Mil) to Feb. 2026 ($0.11 Mil) but then
increased
from Feb. 2026 ($0.11 Mil) to May. 2026 ($0.30 Mil).
CNBX Pharmaceuticals's annual market cap
declined
from Aug. 2023 ($0.38 Mil) to Aug. 2024 ($0.19 Mil) but then
increased
from Aug. 2024 ($0.19 Mil) to Aug. 2025 ($0.28 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. CNBX Pharmaceuticals's Enterprise Value for Today is $1.48 Mil.
CNBX Pharmaceuticals (OTCPK:CNBX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
CNBX Pharmaceuticals Market Cap Related Terms
CNBX Pharmaceuticals Market Cap Historical Data
* Premium members only.
The historical data trend for CNBX Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CNBX Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CNBX Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where CNBX Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
CNBX Pharmaceuticals's Market Cap for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CNBX Pharmaceuticals (CNBX) has a Market Cap of $0.32 Mil as of Aug. 27, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CNBX Pharmaceuticals and its competitors. According to the industry distribution chart, CNBX Pharmaceuticals ranks #1409 out of 1421 companies in the Biotechnology industry, placing it in the top 99.2%.
Is CNBX Pharmaceuticals' Market Cap too high?
CNBX Pharmaceuticals' current Market Cap is $0.32 Mil. The Biotechnology industry median Market Cap is 123.29. CNBX Pharmaceuticals' value of $0.32 Mil is 99.7% below this industry median. Based on the distribution chart, CNBX Pharmaceuticals ranks #1409 out of 1421 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does CNBX Pharmaceuticals' Market Cap compare to SIGY and LIPO?
According to the Biotechnology industry distribution chart, CNBX Pharmaceuticals ranks #1409 out of 1421 companies for Market Cap. This places CNBX Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 123.29. CNBX Pharmaceuticals' value of $0.32 Mil is 99.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 123.29, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CNBX Pharmaceuticals's current Market Cap of $0.32 Mil is 99.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on CNBX Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 123.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CNBX Pharmaceuticals's current Market Cap is $0.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CNBX Pharmaceuticals stock overvalued right now?
CNBX Pharmaceuticals (CNBX) has a current Market Cap of $0.32 Mil. The current Market Cap is $0.32 Mil and 99.7% below the Biotechnology industry median of 123.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For CNBX Pharmaceuticals (CNBX), the current Market Cap is $0.32 Mil as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CNBX Pharmaceuticals Inc is a clinical-stage biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the Cannabics SR, an oral capsule developed for the treatment of patients with cancer and cancer anorexia cachexia syndrome (CACS). It also has an anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) named RCC-33.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNBX has been successfully added to your 
